SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care, presented updated data for Marqibo(r) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse and data from metastatic uveal melanoma at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 29-June 2, 2009 in Orlando, Florida.
